Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer

• Published in: Cancer chemotherapy and pharmacology 2009, Vol.63 (2), p.253-260
• Main Authors: Kim, Yeul Hong, Seo, Hee Yeon, Jeen, Yoon Tae, Kim, Hoon-Kyo, Shim, Byoung Yong, Yang, Jinmo
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Cancer Research; Carcinoma - drug therapy; Carcinoma - pathology; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Male; Maximum Tolerated Dose; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Oxonic Acid - administration & dosage; Oxonic Acid - therapeutic use; Pharmacology. Drug treatments; Pharmacology/Toxicology; Prospective Studies; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Taxoids - administration & dosage; Taxoids - therapeutic use; Tegafur - administration & dosage; Tegafur - therapeutic use; Treatment Outcome; Tumors
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-008-0734-6

Background The primary objectives of this study were to estimate the maximum-tolerated dose (MTD) of docetaxel in combination with a fixed dose of S-1 and to determine the recommended dose (RD). Patients and methods Patients with histologically proven gastric carcinoma with metastatic or locally advanced inoperable disease were eligible. Patients received intravenous docetaxel starting at 40 mg/m 2 (dose level 1), and stepwise dose increases to 50, 60, and 70 mg/m 2 were planned for successive patient cohorts (dose levels 2, 3, and 4, respectively) over 1 h on day 1 and oral S-1 administered at a fixed dose of 40 mg/m 2 twice daily on days 1–14, both drugs every 21 days. Results A total of 13 patients were enrolled into this trial. All three patients at dose level 3 developed dose-limiting toxicities (DLT), and this level was declared to be the MTD. Hence, level 2 (docetaxel 50 mg/m 2 ) was declared to be the RD for the next study. As 9 of the 13 enrolled patients responded to treatment, the overall objective response rate was 69.2% (95% CI, 44.1–94.3%). The median time to progression was 8.38 months (range 1.44–8.51) and the overall survival duration was 9.9 months (range 0.62–11.57). The most common grade 3/4 toxicity of docetaxel plus S-1 was neutropenia, which was tolerable and manageable. Conclusion This regimen showed encouraging activity and a manageable safety profile in advanced gastric carcinoma and could be used in further randomized studies.